Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte S p H 7.4 is an isotonic crystalloid solution that expands intravascular volume and replaces extracellular fluid losses. It provides electrolytes (sodium, chloride, potassium, magnesium, acetate, gluconate) to maintain acid-base balance and osmotic pressure. Acetate and gluconate are metabolized to bicarbonate, providing alkalinizing effect.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
FDA-approved: Replacement of extracellular fluid losses in patients who require fluid resuscitation or maintenance, particularly in metabolic acidosis or mild to moderate acid-base disturbances.,Off-label: Not commonly used off-label; may be used in specific electrolyte imbalances or perioperative settings where balanced crystalloid is preferred.
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Intravenous infusion; dose depends on fluid and electrolyte needs, typically 500-3000 m L/24 hours for adults.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Not applicable (components are endogenous substances; half-life reflects renal clearance and volume status, typically 2-4 hours for sodium and chloride in euvolemic patients).
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Acetate and gluconate are metabolized primarily in the liver and peripheral tissues to bicarbonate ions. Electrolytes are excreted or reabsorbed via renal mechanisms.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Renal: 100% (electrolytes and buffer components are excreted unchanged by the kidneys; no biliary or fecal elimination).
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
0% (electrolytes and buffer components are not protein-bound; free in plasma).
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Sodium: 0.15-0.3 L/kg (extracellular fluid space); Chloride: similar; Bicarbonate precursor (acetate/gluconate): distributed in total body water (~0.6 L/kg).
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Intravenous: 100% (directly administered into bloodstream); not applicable to other routes.
Intravenous: 100%.
No specific dosage adjustment; use with caution in severe renal impairment due to risk of electrolyte imbalances and fluid overload.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
No specific dosage adjustment; monitor for electrolyte disturbances and fluid overload.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Weight-based: 100-150 m L/kg/24 hours for maintenance; adjust based on clinical condition and electrolyte requirements.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Use with caution due to increased risk of fluid overload and electrolyte imbalances; start at lower end of dosing range and monitor closely.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
No FDA black box warning.
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Use with caution in patients with congestive heart failure, severe renal impairment, hyponatremia, hyperkalemia, hypermagnesemia, or conditions predisposing to fluid overload.,May cause fluid and/or solute overload, pulmonary edema, or electrolyte disturbances.,Monitor serum electrolytes, fluid balance, and acid-base status during prolonged therapy.
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Hypersensitivity to any component.,Severe hyperkalemia or severe hypernatremia.,Patients with significant fluid overload or severe metabolic alkalosis.,Concurrent use with products containing calcium (risk of precipitation in IV line, though not directly contraindicated with this product, but caution).
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
No known food interactions. However, oral intake may be restricted or modified based on underlying condition (e.g., bowel rest, NPO status).
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
Isolyte S p H 7.4 is a balanced electrolyte solution with no known teratogenic effects in humans. No fetal risks are identified in any trimester when used appropriately for fluid and electrolyte replacement.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Isolyte S p H 7.4 constituents are normal components of body fluids and breast milk. No specific M/P ratio is available; however, there is no expected risk to the nursing infant when the solution is used as indicated.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
Pregnancy may alter fluid and electrolyte requirements due to increased plasma volume and glomerular filtration rate. Dosing should be individualized based on maternal status; no fixed dose adjustment is necessary, but careful monitoring of volume status is recommended.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
ISOLYTE S p H 7.4 is a balanced isotonic crystalloid solution containing multiple electrolytes (sodium, potassium, magnesium, calcium, acetate, gluconate) and is buffered to p H 7.4. It is indicated for use as a replacement fluid in extracellular volume depletion (e.g., dehydration, burns, surgery) and for maintenance fluid therapy. Avoid use in patients with hyperkalemia, hypercalcemia, or severe metabolic alkalosis. The acetate and gluconate act as bicarbonate precursors, making it suitable for correcting mild metabolic acidosis. In patients with renal impairment, monitor electrolytes closely due to risk of accumulation. Do not confuse with ISOLYTE S without p H adjustment (which may have different buffer composition).
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
This solution is given intravenously to replace lost fluids and electrolytes.,Tell your healthcare provider if you have kidney disease, heart disease, or any electrolyte imbalances.,Report any signs of fluid overload, such as shortness of breath, swelling in ankles or feet, or rapid weight gain.,Do not drive or operate heavy machinery until you know how this medication affects you.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep all appointments for blood tests to monitor electrolyte levels.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE S PH 7.4 IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte S p H 7.4 is an isotonic crystalloid solution that expands intravascular volume and replaces extracellular fluid losses. It provides electrolytes (sodium, chloride, potassium, magnesium, acetate, gluconate) to maintain acid-base balance and osmotic pressure. Acetate and gluconate are metabolized to bicarbonate, providing alkalinizing effect.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE S PH 7.4 IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE S PH 7.4 IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte needs, typically 500-3000 m L/24 hours for adults.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE S PH 7.4 IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE S PH 7.4 IN PLASTIC CONTAINER is classified as Category C. Isolyte S pH 7.4 is a balanced electrolyte solution with no known teratogenic effects in humans. No fetal risks are identified in any trimester when used appropriately for fluid an. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.